Loading
A phase 1/2 trial of TYK-00540 in HR-positive / HER2-negative breast cancer, run by TYK Medicines, Inc, now recruiting.
Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06950086 by TYK Medicines, Inc, with 180 participants planned, started 2024-01-02 and due to reach its primary completion in 2026-09. Interventions recorded: TYK-00540.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares TYK Medicines and the tag pipeline.
Shares TYK Medicines and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/